In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer

PURPOSE: Breast cancer is the most frequently diagnosed cancer globally, and the leading cause of cancer-associated mortality among women. The efficacy of most clinical chemotherapies is often limited by poor pharmacokinetics and the development of drug resistance by tumors. In a continuing effort t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawal, Bashir, Kuo, Yu-Cheng, Sumitra, Maryam Rachmawati, Wu, Alexander T H, Huang, Hsu-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473721/
https://www.ncbi.nlm.nih.gov/pubmed/34588796
http://dx.doi.org/10.2147/JIR.S329401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473721/
https://www.ncbi.nlm.nih.gov/pubmed/34588796
http://dx.doi.org/10.2147/JIR.S329401

Ejemplares similares